AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system
- PMID: 25873306
- PMCID: PMC4720176
- DOI: 10.1177/1759091415569908
AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system
Abstract
Sandhoff disease (SD) is an autosomal recessive neurodegenerative disease caused by a mutation in the gene for the β-subunit of β-N-acetylhexosaminidase (Hex), resulting in the inability to catabolize ganglioside GM2 within the lysosomes. SD presents with an accumulation of GM2 and its asialo derivative GA2, primarily in the central nervous system. Myelin-enriched glycolipids, cerebrosides and sulfatides, are also decreased in SD corresponding with dysmyelination. At present, no treatment exists for SD. Previous studies have shown the therapeutic benefit of adeno-associated virus (AAV) vector-mediated gene therapy in the treatment of SD in murine and feline models. In this study, we treated presymptomatic SD cats with AAVrh8 vectors expressing feline Hex in the thalamus combined with intracerebroventricular (Thal/ICV) injections. Treated animals showed clearly improved neurologic function and quality of life, manifested in part by prevention or attenuation of whole-body tremors characteristic of untreated animals. Hex activity was significantly elevated, whereas storage of GM2 and GA2 was significantly decreased in tissue samples taken from the cortex, cerebellum, thalamus, and cervical spinal cord. Treatment also increased levels of myelin-enriched cerebrosides and sulfatides in the cortex and thalamus. This study demonstrates the therapeutic potential of AAV for feline SD and suggests a similar potential for human SD patients.
Keywords: Sandhoff disease; adeno-associated virus; ganglioside; gene therapy; β-hexosaminidase.
© The Author(s) 2015.
Figures






Similar articles
-
Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.Gene Ther. 2015 Feb;22(2):181-9. doi: 10.1038/gt.2014.108. Epub 2014 Dec 4. Gene Ther. 2015. PMID: 25474439
-
AAV-mediated gene delivery attenuates neuroinflammation in feline Sandhoff disease.Neuroscience. 2017 Jan 6;340:117-125. doi: 10.1016/j.neuroscience.2016.10.047. Epub 2016 Oct 26. Neuroscience. 2017. PMID: 27793778 Free PMC article.
-
Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.Exp Neurol. 2015 Jan;263:102-12. doi: 10.1016/j.expneurol.2014.09.020. Epub 2014 Oct 5. Exp Neurol. 2015. PMID: 25284324 Free PMC article.
-
[Recent advances in molecular genetics of GM2 gangliosidosis].Nihon Rinsho. 1995 Dec;53(12):2988-93. Nihon Rinsho. 1995. PMID: 8577047 Review. Japanese.
-
Biology and potential strategies for the treatment of GM2 gangliosidoses.Mol Med Today. 1998 Apr;4(4):158-65. doi: 10.1016/s1357-4310(98)01227-1. Mol Med Today. 1998. PMID: 9572057 Review.
Cited by
-
AAV gene therapy for Tay-Sachs disease.Nat Med. 2022 Feb;28(2):251-259. doi: 10.1038/s41591-021-01664-4. Epub 2022 Feb 10. Nat Med. 2022. PMID: 35145305 Free PMC article.
-
Animal Model Contributions to Congenital Metabolic Disease.Adv Exp Med Biol. 2020;1236:225-244. doi: 10.1007/978-981-15-2389-2_9. Adv Exp Med Biol. 2020. PMID: 32304075 Free PMC article. Review.
-
Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis.Mol Ther Methods Clin Dev. 2022 Mar 16;25:170-189. doi: 10.1016/j.omtm.2022.03.011. eCollection 2022 Jun 9. Mol Ther Methods Clin Dev. 2022. PMID: 35434178 Free PMC article.
-
Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.Hum Gene Ther. 2017 Jun;28(6):510-522. doi: 10.1089/hum.2016.109. Epub 2017 Jan 26. Hum Gene Ther. 2017. PMID: 28132521 Free PMC article.
-
Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model.Mol Ther Methods Clin Dev. 2018 Oct 26;12:47-57. doi: 10.1016/j.omtm.2018.10.011. eCollection 2019 Mar 15. Mol Ther Methods Clin Dev. 2018. PMID: 30534578 Free PMC article.
References
-
- Ando S., Chang N. C., Yu R. K. (1978) High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. Analytical Biochemistry 89: 437–450. - PubMed
-
- Baek R. C., Kasperzyk J. L., Platt F. M., Seyfried T. N. (2008) N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochemistry International 52: 1125–1133. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous